Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

NCT01878617 is registered in ClinicalTrials.gov with St. Jude Children's Research Hospital as lead sponsor.

NCT NCT01878617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01878617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Lead sponsor
St. Jude Children's Research Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 23, 2013
Completion date
October 13, 2031
Enrollment
660 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

medulloblastoma